A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies

Olivier Hermine; Juan Carlos Ramos; Kensei Tobinai

doi:10.1007/s12325-018-0658-4

A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies

Olivier Hermine, Juan Carlos Ramos, Kensei Tobinai

Medicine

Research output: Contribution to journal › Review article › peer-review

38 Scopus citations

Abstract

Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.

Original language	English (US)
Pages (from-to)	135-152
Number of pages	18
Journal	Advances in Therapy
Volume	35
Issue number	2
DOIs	https://doi.org/10.1007/s12325-018-0658-4
State	Published - Feb 1 2018

Keywords

Adult T-cell leukemia–lymphoma
Chemotherapy
Human T-cell lymphotropic virus type 1
Oncology
Relapsed/refractory disease
Targeted agents

ASJC Scopus subject areas

Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12325-018-0658-4

Cite this

@article{83c1c3cb19fd4f188172f2ac72ef845e,

title = "A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies",

abstract = "Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.",

keywords = "Adult T-cell leukemia–lymphoma, Chemotherapy, Human T-cell lymphotropic virus type 1, Oncology, Relapsed/refractory disease, Targeted agents",

author = "Olivier Hermine and Ramos, {Juan Carlos} and Kensei Tobinai",

note = "Funding Information: Disclosures. Olivier Hermine has nothing to declare. Juan Carlos Ramos has nothing to declare. Kensei Tobinai received research funding from Kyowa Hakko Kirin, Celgene, Eisai, Mundipharma, Takeda; and has received honoraria from Eisai, Takeda, Mundipharma, HUYA Bioscience International, Kyowa Hakko Kirin, Celgene. Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

month = feb,

day = "1",

doi = "10.1007/s12325-018-0658-4",

language = "English (US)",

volume = "35",

pages = "135--152",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Health Communications Inc.",

number = "2",

}

TY - JOUR

T1 - A Review of New Findings in Adult T-cell Leukemia–Lymphoma

T2 - A Focus on Current and Emerging Treatment Strategies

AU - Hermine, Olivier

AU - Ramos, Juan Carlos

AU - Tobinai, Kensei

N1 - Funding Information: Disclosures. Olivier Hermine has nothing to declare. Juan Carlos Ramos has nothing to declare. Kensei Tobinai received research funding from Kyowa Hakko Kirin, Celgene, Eisai, Mundipharma, Takeda; and has received honoraria from Eisai, Takeda, Mundipharma, HUYA Bioscience International, Kyowa Hakko Kirin, Celgene. Publisher Copyright: © 2018, The Author(s).

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.

AB - Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.

KW - Adult T-cell leukemia–lymphoma

KW - Chemotherapy

KW - Human T-cell lymphotropic virus type 1

KW - Oncology

KW - Relapsed/refractory disease

KW - Targeted agents

UR - http://www.scopus.com/inward/record.url?scp=85041556246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041556246&partnerID=8YFLogxK

U2 - 10.1007/s12325-018-0658-4

DO - 10.1007/s12325-018-0658-4

M3 - Review article

C2 - 29411267

AN - SCOPUS:85041556246

VL - 35

SP - 135

EP - 152

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 2

ER -

A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this